

## STRESS-L, resource

---

**From:** Essex.REC@hra.nhs.uk <noreply@harp.org.uk>  
**Sent:** 19 March 2020 11:04  
**To:** tony.whitehouse@uhb.nhs.uk; STRESS-L, resource  
**Cc:** research.amendments@hscni.net; HCRW.amendments@wales.nhs.uk  
**Subject:** IRAS 213669. Amendment confirmation of REC Validation, categorisation and implementation information  
**Attachments:** IRAS213669 - validated amendment - 19-03-2020.pdf  
**Categories:** Emma to action

### Amendment Confirmation of REC Validation, Categorisation and Implementation Information

Dear Dr Whitehouse,

<b>IRAS Project ID:</b>	213669
<b>Short Study Title:</b>	Study into the Reversal of Septic Shock with Landiolol (Beta Blockade)
<b>Date complete amendment submission received:</b>	06 March 2020
<b>Amendment No./ Sponsor Ref:</b>	Substantial Amendment 14
<b>Amendment Date:</b>	19 February 2020
<b>Amendment Type:</b>	Substantial
<b>Outcome of HRA and HCRW Assessment</b>	HRA and HCRW Approval for the amendment will be separately confirmed by email.
<b>Implementation date in NHS organisations in England and/or Wales</b>	35 days from date amendment information together with this email, is supplied to participating organisations <b>(provided HRA and HCRW Approval for the amendment is in place and conditions are met)</b>
<b>Implementation date in NHS/HSC organisations in Northern Ireland and/or Scotland (remove row if no sites in NI or Scotland)</b>	25/03/2020
For NHS/HSC R&D Office information	
<b>Amendment Category</b>	A

Thank you for submitting an amendment to your project. We have now categorised your amendment and please find this, as well as other relevant information, in the table above.

Please also find attached a copy of the REC validation letter for the submitted amendment.

#### What should I do next?

Please read the information in [IRAS](#), which provides you with information on how and when you can implement your amendment at NHS/HSC sites in each nation, and what actions you should take now.

If you have participating NHS/HSC organisations in any other UK nations that are affected by this amendment please note that **we will** forward the amendment submission to the relevant national coordinating function(s).

If not already provided, please email to us any regulatory approvals (where applicable) once available. Your amendment will be reviewed by the REC, as per the attached letter.

### **When can I implement this amendment?**

You may implement this amendment in line with the information in [IRAS](#). Please note that you may only implement changes described in the amendment notice.

### **Who should I contact if I have further questions about this amendment?**

If you have any questions about the ethical review of this amendment, please do not hesitate to contact me.

If you have any other questions about this amendment please contact the relevant national coordinating centre for advice:

- England – [amendments@hra.nhs.uk](mailto:amendments@hra.nhs.uk)
- Northern Ireland – [research.gateway@hscni.net](mailto:research.gateway@hscni.net)
- Scotland – [nhsq.NRSPCC@nhs.net](mailto:nhsq.NRSPCC@nhs.net)
- Wales – [HCRW.amendments@wales.nhs.uk](mailto:HCRW.amendments@wales.nhs.uk)

Additional information on the management of amendments can be found in the [IRAS guidance](#).

Please do not hesitate to contact me if you require further information.

Kind regards

**Henrietta Phillips**

**Health Research Authority**

Ground Floor | Skipton House | 80 London Road | London | SE1 6LH

**E.** [amendments@hra.nhs.uk](mailto:amendments@hra.nhs.uk)

**W.** [www.hra.nhs.uk](http://www.hra.nhs.uk)

Sign up to receive our newsletter [HRA Latest](#).